Page last updated: 2024-12-11

aspidospermidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

aspidospermidine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6857472
CHEBI ID38486
SCHEMBL ID9082745
MeSH IDM0364622

Synonyms (11)

Synonym
CHEBI:38486
aspidospermidine
SCHEMBL9082745
2912-09-6
(1r,9r,12r,19r)-12-ethyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6-triene
(1r,9r,12r,19s)-12-ethyl-8,16-diazapentacyclo(10.6.1.01,9.02,7.016,19)nonadeca-2,4,6-triene
38ev97nhy2 ,
aspidospermidine, (+)-
[3ar-(3aalpha,5abeta,10br*,13aalpha)]-3a-ethyl-2,3,3a,4,5,5a,6,11,12,13a-decahydro-1h-indolizino[8,1-cd]carbazole
1h-indolizino[8,1-cd]carbazole, 3a-ethyl-2,3,3a,4,5,5a,6,11,12,13a-decahydro-, [3ar-(3aalpha,5abeta,10br*,13aalpha)]-
DTXSID301045567

Research Excerpts

Effects

ExcerptReferenceRelevance
"(±)-Aspidospermidine (1) has been synthesized from the commercially available 2,3-dihydro-1H-carbazol-4(9H)-one 6 in 10 steps with 20% overall yield. "( Concise total synthesis of (±)-aspidospermidine.
Jing, P; Ma, H; She, X; Xie, X; Zhang, W, 2015
)
1.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
indole alkaloid fundamental parent
Aspidosperma alkaloidAny member of a group of indole alkaloids based on a C19 or C20 skeleton formed by condensation of tryptamine with a rearranged seconloganin-derived C9 or C10 unit. The Aspidosperma alkaloids constitute the largest group of indole alkaloids (currently ca. 220 alkaloids) and may be divided into several sub-groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (32)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's13 (40.63)29.6817
2010's18 (56.25)24.3611
2020's1 (3.13)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.72 (24.57)
Research Supply Index3.50 (2.92)
Research Growth Index4.98 (4.65)
Search Engine Demand Index56.46 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.13%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other31 (96.88%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]